<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436500</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-IFE-001</org_study_id>
    <nct_id>NCT01436500</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokinetics of Ifetroban Injection in Hepatorenal Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cumberland Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of ifetroban in the treatment of hepatorenal syndrome (HRS) in hospitalized adult
      patients to assess the safety and pharmacokinetics of 3 days of intravenous ifetroban.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Half-life (T-1/2) of Ifetroban and Ifetroban Acylglucuronide</measure>
    <time_frame>3 days</time_frame>
    <description>Plasma concentrations of ifetroban and its major active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters (Exposure) of Ifetroban and Ifetroban Acylglucuronide After Three Days of Treatment</measure>
    <time_frame>3 days</time_frame>
    <description>Plasma concentrations of ifetroban and its primary active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameters (Concentration) of Ifetroban and Ifetroban Acylglucuronide After Three Days of Treatment</measure>
    <time_frame>3 days</time_frame>
    <description>Plasma concentrations of ifetroban and it's major active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Day 28 Mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Achieving a Treatment-period Serum Creatinine Reduction Below 1.5 mg/dL</measure>
    <time_frame>Day 0 through Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage of Patients Achieving a Reduction of Creatinine Clearance to Below Baseline on Two Consecutive Daily Measurements</measure>
    <time_frame>Day 0 to Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 24-hour Urine Volume</measure>
    <time_frame>Baseline to Hour 96</time_frame>
    <description>The volume of urine collected in a 24-hour post-treatment period minus the volume collected in a 24-hour pre-treatment period.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Hepatorenal Syndrome</condition>
  <arm_group>
    <arm_group_label>5 mg ifetroban, Type 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Type 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 1 HRS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg ifetroban, Type 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg ifetroban, Type 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg ifetroban, Type 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg ifetroban, Type 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg ifetroban, Type 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>150 mg ifetroban, Type 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Type 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60-minute intravenous infusion of 5% dextrose in sterile water given once daily for 3 days to subjects with Type 2 HRS.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifetroban Injection</intervention_name>
    <description>Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
    <arm_group_label>5 mg ifetroban, Type 1</arm_group_label>
    <arm_group_label>5 mg ifetroban, Type 2</arm_group_label>
    <arm_group_label>15 mg ifetroban, Type 1</arm_group_label>
    <arm_group_label>15 mg ifetroban, Type 2</arm_group_label>
    <arm_group_label>50 mg ifetroban, Type 1</arm_group_label>
    <arm_group_label>50 mg ifetroban, Type 2</arm_group_label>
    <arm_group_label>150 mg ifetroban, Type 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile water with 5% Dextrose</description>
    <arm_group_label>Placebo, Type 1</arm_group_label>
    <arm_group_label>Placebo, Type 2</arm_group_label>
    <other_name>D5W</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic liver disease, defined as cirrhosis with ascites based on clinical findings
             (biopsy not necessary).

          2. Subjects with either Type 1 or Type 2 HRS defined in a and b below:

             a. Type 1: i. At least a doubling of the serum creatinine to a minimum of 220 µmol/L
             (2.5 mg/dL) at enrollment, occurring over a period of less than 14 days, OR ii. A 50%
             or greater reduction in the estimated glomerular filtration rate (GFR - calculated by
             the method of Cockcroft-Gault) to below 20 mL/min at enrollment occurring over a
             period of less than 14 days.

             iii. A projected doubling of serum creatinine to a minimum of 2.5 mg/dL, expected to
             occur in less than 14 days based on the rate of change observed.

             b. Type 2: defined as at least a 33% reduction in creatinine clearance occurring over
             a period of greater than 2 weeks, with a serum creatinine (SCr) &gt; 133µmol/L (1.5
             mg/dL).

          3. Oliguria occurring within 48 hours prior to the first administration CTM. Oliguria is
             defined as an average urine output of &lt; 35 mL/hr (measured for a minimum of 4 hours)
             under either of the following circumstances:

             a. When measured central venous pressure (CVP) &gt; 12 mmHg, OR b. following a fluid
             challenge consisting of either: i. at minimum 20 mL/kg isotonic fluid (e.g. any
             combination of 5% albumin, normal saline, blood or blood products) given over no more
             than 6 hours ii. at minimum 1 g/kg of hypertonic fluid (e.g. 25% albumin) given over
             no more than 24 hours iii. an equivalent combination of 3.b.i and 3.b.ii

        Exclusion Criteria:

          1. History of allergy or hypersensitivity to ifetroban

          2. Pregnant or nursing

          3. Less than 18 years of age

          4. Serum creatinine at the time of enrollment greater than or equal to 5.0 mg/dL

          5. Platelet count at screening less than 30 x 10^3 platelets/µL

          6. Anticipated of planned need for dialysis within 5 days of first CTM dose.

          7. Active gastrointestinal hemorrhage (where active is defined as evidence of bleeding
             within 48 hours of the first dose of CTM)

          8. Evidence of current (within past 30 days) obstructive (post-renal) or intrinsic renal
             disease [including but not limited to: acute tubular necrosis (ATN), glomerular
             diseases/glomerulonephritis, acute interstitial nephritis (AIN), known urinary
             obstruction, proteinuria &gt; 500 mg/day, microhematuria (&gt; 50 RBCs/high power field),
             abnormal renal ultrasound, fractional excretion of sodium (FeNa) &gt; 2.0%, any urinary
             casts other than hyaline.

          9. Current or recent (within the preceding 5 days) treatment with nephrotoxic drugs
             including but not limited to: NSAIDs (prior 48 hours), angiotensin converting enzyme
             (ACE) inhibitors, angiotensin receptor blockers (ARB), calcineurin inhibitors
             (cyclosporine, tacrolimus), aminoglycosides, amphotericin B, antiretrovirals and
             antivirals (adefovir, cidofovir, tenofovir, acyclovir, indinavir), cisplatin,
             methotrexate, cyclosporine, amphotericin B contrast agents, foscarnet, zoledronate,
             etc.

         10. Presence of shock defined as hypotension, with a mean arterial pressure less than 50
             mmHG.

         11. New York Heart Association class 3 or 4 heart failure.

         12. Presence of hepatocellular carcinoma not transplantable by Milan criteria

         13. Cardiopulmonary arrest without full recovery of mental status

         14. Moribund and death expected within five days

         15. Bacterial or fungal infections which have been unresponsive to at least 24 hours of
             appropriate antimicrobial therapy

         16. Burns &gt; 30% body surface area

         17. Exposed to investigational drugs within 30 days before 1st CTM administration.

         18. Inability to understand the requirements of the study. (Subjects must be willing to
             provide written informed consent or consent of legally recognized representative, as
             evidenced by signature on an informed consent document approved by an Institutional
             Review Board [IRB], and agree to abide by the study restrictions. If the subject is
             incapacitated, informed consent will be sought from a legally recognized
             representative).

         19. Refusal to provide written authorization for use and disclosure of protected health
             information.

         20. Be otherwise unsuitable for the study, in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan McGuire, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD, Hillcrest Medical Center Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF (University of California-San Francisco)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University (Division of Gastroenterology/Hepatology)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor All Saints Medical Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Sciences Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MIDAS Multispeciality Hospital PVT LTD</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <results_first_submitted>December 22, 2016</results_first_submitted>
  <results_first_submitted_qc>December 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 14, 2017</results_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatorenal Syndrome</keyword>
  <keyword>HRS</keyword>
  <keyword>ifetroban</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hepatorenal Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ifetroban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>5 mg Ifetroban</title>
          <description>5 mg Ifetroban Injection administered IV over 60 minutes once daily x 3 days</description>
        </group>
        <group group_id="P2">
          <title>15 mg Ifetroban</title>
          <description>15 mg Ifetroban Injection administered IV over 60 minutes once daily x 3 days</description>
        </group>
        <group group_id="P3">
          <title>50 mg Ifetroban</title>
          <description>50 mg Ifetroban Injection administered IV over 60 minutes once daily x 3 days</description>
        </group>
        <group group_id="P4">
          <title>150 mg Ifetroban</title>
          <description>150 mg Ifetroban Injection administered IV over 60 minutes once daily x 3 days</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>5% Dextrose in Water administered IV over 60 minutes once daily x 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>liver transplant</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>initiation of dialysis</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>discontinued study drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>not specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ifetroban Injection</title>
          <description>5, 15, 50, or 150 mg Ifetroban Injection administered IV over 60 minutes once daily x 3 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>5% Dextrose in Water administered IV over 60 minutes once daily x 3 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="9.7"/>
                    <measurement group_id="B2" value="56" spread="6.4"/>
                    <measurement group_id="B3" value="57" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Half-life (T-1/2) of Ifetroban and Ifetroban Acylglucuronide</title>
        <description>Plasma concentrations of ifetroban and its major active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters.</description>
        <time_frame>3 days</time_frame>
        <population>Patients from which a full series of plasma samples were obtained from baseline through Hour 72 were included in the calculations of the PK parameters. Where the number of participants analyzed in an arm is lower than the number exposed for that arm, the patients with missing data did not contribute to the calculation of the PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Ifetroban, Type 1</title>
            <description>60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O2">
            <title>5 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O3">
            <title>15 mg Ifetroban, Type 1</title>
            <description>60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O4">
            <title>15 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O5">
            <title>50 mg Ifetroban, Type 1</title>
            <description>60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O6">
            <title>50 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O7">
            <title>150 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (T-1/2) of Ifetroban and Ifetroban Acylglucuronide</title>
          <description>Plasma concentrations of ifetroban and its major active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters.</description>
          <population>Patients from which a full series of plasma samples were obtained from baseline through Hour 72 were included in the calculations of the PK parameters. Where the number of participants analyzed in an arm is lower than the number exposed for that arm, the patients with missing data did not contribute to the calculation of the PK parameters.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>half-life ifetroban</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0">No SD available with a sample of 2.</measurement>
                    <measurement group_id="O2" value="11.9" spread="18.4"/>
                    <measurement group_id="O3" value="15.7" spread="16.7"/>
                    <measurement group_id="O4" value="10.5" spread="8.6"/>
                    <measurement group_id="O5" value="18.1" spread="14.8"/>
                    <measurement group_id="O6" value="13.5" spread="8.2"/>
                    <measurement group_id="O7" value="17.4" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>half-life ifetroban acylglucuronide</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" spread="17.5"/>
                    <measurement group_id="O2" value="14.7" spread="19.9"/>
                    <measurement group_id="O3" value="22.1" spread="9.5"/>
                    <measurement group_id="O4" value="18.6" spread="10.9"/>
                    <measurement group_id="O5" value="26.4" spread="22.0"/>
                    <measurement group_id="O6" value="15.2" spread="9.5"/>
                    <measurement group_id="O7" value="12.6" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters (Exposure) of Ifetroban and Ifetroban Acylglucuronide After Three Days of Treatment</title>
        <description>Plasma concentrations of ifetroban and its primary active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters.</description>
        <time_frame>3 days</time_frame>
        <population>Patients from which a full series of plasma samples were obtained from baseline through Hour 72 were included in the calculations of the PK parameters. Where the number of participants analyzed in an arm is lower than the number exposed for that arm, the patients with missing data did not contribute to the calculation of the PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Ifetroban, Type 1</title>
            <description>60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O2">
            <title>5 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O3">
            <title>15 mg Ifetroban, Type 1</title>
            <description>60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O4">
            <title>15 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O5">
            <title>50 mg Ifetroban, Type 1</title>
            <description>60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O6">
            <title>50 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O7">
            <title>150 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters (Exposure) of Ifetroban and Ifetroban Acylglucuronide After Three Days of Treatment</title>
          <description>Plasma concentrations of ifetroban and its primary active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters.</description>
          <population>Patients from which a full series of plasma samples were obtained from baseline through Hour 72 were included in the calculations of the PK parameters. Where the number of participants analyzed in an arm is lower than the number exposed for that arm, the patients with missing data did not contribute to the calculation of the PK parameters.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ifetroban area under the curve (AUC) to 24 hours</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="964" spread="683"/>
                    <measurement group_id="O2" value="779" spread="326"/>
                    <measurement group_id="O3" value="2025" spread="639"/>
                    <measurement group_id="O4" value="2463" spread="1497"/>
                    <measurement group_id="O5" value="5151" spread="3579"/>
                    <measurement group_id="O6" value="6634" spread="2166"/>
                    <measurement group_id="O7" value="18612" spread="8408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ifetroban AUC to infinity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2476">Only 2 subjects were deemed evaluable for this analysis by the pharmacokineticist and SD cannot be calculated with a sample size of 2.</measurement>
                    <measurement group_id="O2" value="906" spread="481"/>
                    <measurement group_id="O3" value="2959" spread="1941"/>
                    <measurement group_id="O4" value="3259" spread="2866"/>
                    <measurement group_id="O5" value="6505" spread="4032"/>
                    <measurement group_id="O6" value="8204" spread="3461"/>
                    <measurement group_id="O7" value="24657" spread="13425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ifetroban acylglucuronide AUC to 24 hours to</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4371" spread="2050"/>
                    <measurement group_id="O2" value="4145" spread="781"/>
                    <measurement group_id="O3" value="12192" spread="2102"/>
                    <measurement group_id="O4" value="12038" spread="2734"/>
                    <measurement group_id="O5" value="46455" spread="2906"/>
                    <measurement group_id="O6" value="42051" spread="18567"/>
                    <measurement group_id="O7" value="109915" spread="32895"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ifetroban acylglucuronide AUC to infinity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="5"/>
                    <count group_id="O7" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8440" spread="8730"/>
                    <measurement group_id="O2" value="6128" spread="3721"/>
                    <measurement group_id="O3" value="21962" spread="7404"/>
                    <measurement group_id="O4" value="29857" spread="27688"/>
                    <measurement group_id="O5" value="86457" spread="44928"/>
                    <measurement group_id="O6" value="61673" spread="25672"/>
                    <measurement group_id="O7" value="144951" spread="61311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Parameters (Concentration) of Ifetroban and Ifetroban Acylglucuronide After Three Days of Treatment</title>
        <description>Plasma concentrations of ifetroban and it's major active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters.</description>
        <time_frame>3 days</time_frame>
        <population>Patients from which a full series of plasma samples were obtained from baseline through Hour 72 were included in the calculations of the PK parameters. Where the number of participants analyzed in an arm is lower than the number exposed for that arm, the patients with missing data did not contribute to the calculation of the PK parameters.</population>
        <group_list>
          <group group_id="O1">
            <title>5 mg Ifetroban, Type 1</title>
            <description>60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O2">
            <title>5 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 5 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O3">
            <title>15 mg Ifetroban, Type 1</title>
            <description>60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O4">
            <title>15 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 15 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O5">
            <title>50 mg Ifetroban, Type 1</title>
            <description>60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 1 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O6">
            <title>50 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 50 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
          <group group_id="O7">
            <title>150 mg Ifetroban, Type 2</title>
            <description>60-minute intravenous infusion of 150 mg ifetroban given once daily for 3 days to subjects with Type 2 HRS.
Ifetroban Injection: Ifetroban sodium injectable, diluted in sterile water with 5% dextrose</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Parameters (Concentration) of Ifetroban and Ifetroban Acylglucuronide After Three Days of Treatment</title>
          <description>Plasma concentrations of ifetroban and it's major active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters.</description>
          <population>Patients from which a full series of plasma samples were obtained from baseline through Hour 72 were included in the calculations of the PK parameters. Where the number of participants analyzed in an arm is lower than the number exposed for that arm, the patients with missing data did not contribute to the calculation of the PK parameters.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Minimum Concentration Ifetroban</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="4.1"/>
                    <measurement group_id="O2" value="3.4" spread="4.0"/>
                    <measurement group_id="O3" value="14.1" spread="22.6"/>
                    <measurement group_id="O4" value="23.5" spread="33.7"/>
                    <measurement group_id="O5" value="43.3" spread="36.2"/>
                    <measurement group_id="O6" value="51.1" spread="44.5"/>
                    <measurement group_id="O7" value="150.0" spread="115.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Concentration Ifetroban</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="483" spread="445"/>
                    <measurement group_id="O2" value="251" spread="107"/>
                    <measurement group_id="O3" value="581" spread="114"/>
                    <measurement group_id="O4" value="785" spread="225"/>
                    <measurement group_id="O5" value="1666" spread="1478"/>
                    <measurement group_id="O6" value="2599" spread="838"/>
                    <measurement group_id="O7" value="6790" spread="2777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimum Concentration Ifetroban Acylglucuronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.4" spread="56.7"/>
                    <measurement group_id="O2" value="41.4" spread="33.1"/>
                    <measurement group_id="O3" value="241.9" spread="89.0"/>
                    <measurement group_id="O4" value="200.2" spread="114.3"/>
                    <measurement group_id="O5" value="778.0" spread="583.2"/>
                    <measurement group_id="O6" value="632.9" spread="302.9"/>
                    <measurement group_id="O7" value="1755.0" spread="792.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximum Concentration Ifetroban Acylglucuronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384" spread="103"/>
                    <measurement group_id="O2" value="448" spread="101"/>
                    <measurement group_id="O3" value="912" spread="194"/>
                    <measurement group_id="O4" value="1214" spread="255"/>
                    <measurement group_id="O5" value="4737" spread="543"/>
                    <measurement group_id="O6" value="4666" spread="1748"/>
                    <measurement group_id="O7" value="10447" spread="2113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Day 28 Mortality</title>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ifetroban Injection</title>
            <description>5, 15, 50, or 150 mg Ifetroban Injection administered IV over 60 minutes once daily x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5% Dextrose in Water administered IV over 60 minutes once daily x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Day 28 Mortality</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Achieving a Treatment-period Serum Creatinine Reduction Below 1.5 mg/dL</title>
        <time_frame>Day 0 through Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ifetroban Injection</title>
            <description>5, 15, 50, or 150 mg Ifetroban Injection administered IV over 60 minutes once daily x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5% Dextrose in Water administered IV over 60 minutes once daily x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Achieving a Treatment-period Serum Creatinine Reduction Below 1.5 mg/dL</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage of Patients Achieving a Reduction of Creatinine Clearance to Below Baseline on Two Consecutive Daily Measurements</title>
        <time_frame>Day 0 to Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ifetroban Injection</title>
            <description>5, 15, 50, or 150 mg Ifetroban Injection administered IV over 60 minutes once daily x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5% Dextrose in Water administered IV over 60 minutes once daily x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients Achieving a Reduction of Creatinine Clearance to Below Baseline on Two Consecutive Daily Measurements</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 24-hour Urine Volume</title>
        <description>The volume of urine collected in a 24-hour post-treatment period minus the volume collected in a 24-hour pre-treatment period.</description>
        <time_frame>Baseline to Hour 96</time_frame>
        <population>Data were missing for the post-treatment urine volume measurements in 9 of 42 ifetroban patients and 3 of 13 placebo patients so they were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Ifetroban Injection</title>
            <description>5, 15, 50, or 150 mg Ifetroban Injection administered IV over 60 minutes once daily x 3 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>5% Dextrose in Water administered IV over 60 minutes once daily x 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 24-hour Urine Volume</title>
          <description>The volume of urine collected in a 24-hour post-treatment period minus the volume collected in a 24-hour pre-treatment period.</description>
          <population>Data were missing for the post-treatment urine volume measurements in 9 of 42 ifetroban patients and 3 of 13 placebo patients so they were excluded from the analysis.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.3" spread="613.3"/>
                    <measurement group_id="O2" value="-118.5" spread="452.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 0 through Day 28</time_frame>
      <desc>A secondary objective of the study was to evaluate the tolerability and safety of ifetroban in HRS patients. All ifetroban patients are grouped together for comparison to all placebo patients for the purpose of maximizing the significance of the evaluation.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ifetroban</title>
          <description>5, 15, 50 or 150 mg Ifetroban Injection administered IV over 60 minutes once daily x 3 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>5% Dextrose in Water administered IV over 60 minutes once daily x 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>worsening ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>peritoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>catheter site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>device failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>chronic hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>hepatorenal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>complications of transplanted liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>worsening coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>chronic hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>worsening renal function</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI can publish data generated at their study site after multi=center study data have already been published, or after 18 months have elapsed following database lock. The sponsor may review manuscripts before submission and delay publication by an additional 60 days, if necessary.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jerry Fox, DVM</name_or_title>
      <organization>Cumberland Pharmaceuticals Inc</organization>
      <phone>615-255-0068</phone>
      <email>jfox@cumberlandpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

